Literature DB >> 8392604

A mutation in the RNA polymerase of poliovirus type 1 contributes to attenuation in mice.

M Tardy-Panit1, B Blondel, A Martin, F Tekaia, F Horaud, F Delpeyroux.   

Abstract

The attenuated Sabin strain of poliovirus type 1 (PV-1) differs from the neurovirulent PV-1 Mahoney strain by 55 nucleotide mutations. Only one of these mutations (A-480-->G, in the 5' noncoding (5' NC) region of the genome, is well characterized, and it confers a strong attenuating effect. We attempted to identify genetic attenuation determinants in the 3'-terminal part of the Sabin 1 genome including the 3D polymerase (3Dpol) gene and the 3' NC region. Previous studies suggested that some of the 11 mutations in this region of the Sabin 1 genome, and in particular a mutation in the polymerase gene (U-6203-->C, Tyr-73-->His), are involved to some extent in the attenuation of PV-1. We analyzed the attenuating effect in the mouse model by using the mouse-adapted PV-1/PV-2 chimeric strain v510 (a Mahoney strain carrying nine amino acids of the VP1 capsid protein from the Lansing strain of PV-2). Mutagenesis of locus 6203 was performed on the original v510 (U-6203-->C) and also on a hybrid v510/Sabin 1 (C-6203-->U) carrying the downstream 1,840 nucleotides of the Sabin 1 genome including the 3Dpol and 3' NC regions. Statistical analysis of disease incidence and time to disease onset in numerous mice inoculated with these strains strongly suggested that nucleotide C-6203 is involved in the attenuation of the Sabin 1 strain. Results also suggested that, among the mutations located in the 3Dpol and 3' NC regions, nucleotide C-6203 may be the principal or the only one to be involved in attenuation in this mouse model. We also found that the effect of C-6203 was weaker than that of nucleotide G-480; the two nucleotides acted independently and may have a cumulative effect on attenuation. The U-6203-->C substitution also appeared to contribute to the thermosensitivity of the Sabin 1 strain.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8392604      PMCID: PMC237848     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  51 in total

1.  Coupled mutations in the 5'-untranslated region of the Sabin poliovirus strains during in vivo passages: structural and functional implications.

Authors:  A R Muzychenko; S V Maslova; Y V Svitkin; E V Pilipenko; B K Nottay; O M Kew; V I Agol
Journal:  Virus Res       Date:  1991-10       Impact factor: 3.303

2.  The natural genomic variability of poliovirus analyzed by a restriction fragment length polymorphism assay.

Authors:  J Balanant; S Guillot; A Candrea; F Delpeyroux; R Crainic
Journal:  Virology       Date:  1991-10       Impact factor: 3.616

3.  Effects of mutations in poliovirus 3Dpol on RNA polymerase activity and on polyprotein cleavage.

Authors:  C C Burns; M A Lawson; B L Semler; E Ehrenfeld
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

4.  Differences in replication of attenuated and neurovirulent polioviruses in human neuroblastoma cell line SH-SY5Y.

Authors:  N La Monica; V R Racaniello
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

5.  Complete nucleotide sequences of all three poliovirus serotype genomes. Implication for genetic relationship, gene function and antigenic determinants.

Authors:  H Toyoda; M Kohara; Y Kataoka; T Suganuma; T Omata; N Imura; A Nomoto
Journal:  J Mol Biol       Date:  1984-04-25       Impact factor: 5.469

Review 6.  Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease.

Authors:  P M Strebel; R W Sutter; S L Cochi; R J Biellik; E W Brink; O M Kew; M A Pallansch; W A Orenstein; A R Hinman
Journal:  Clin Infect Dis       Date:  1992-02       Impact factor: 9.079

7.  Molecular pathogenesis of neural lesions induced by poliovirus type 1.

Authors:  T Couderc; C Christodoulou; H Kopecka; S Marsden; L F Taffs; R Crainic; F Horaud
Journal:  J Gen Virol       Date:  1989-11       Impact factor: 3.891

8.  Transgenic mice susceptible to poliovirus.

Authors:  S Koike; C Taya; T Kurata; S Abe; I Ise; H Yonekawa; A Nomoto
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-01       Impact factor: 11.205

9.  Use of type 1/type 2 chimeric polioviruses to study determinants of poliovirus type 1 neurovirulence in a mouse model.

Authors:  A Martin; D Benichou; T Couderc; J M Hogle; C Wychowski; S Van der Werf; M Girard
Journal:  Virology       Date:  1991-02       Impact factor: 3.616

10.  Engineering a poliovirus type 2 antigenic site on a type 1 capsid results in a chimaeric virus which is neurovirulent for mice.

Authors:  A Martin; C Wychowski; T Couderc; R Crainic; J Hogle; M Girard
Journal:  EMBO J       Date:  1988-09       Impact factor: 11.598

View more
  32 in total

1.  Isolation of an intertypic poliovirus capsid recombinant from a child with vaccine-associated paralytic poliomyelitis.

Authors:  Javier Martín; Elena Samoilovich; Glynis Dunn; Angie Lackenby; Esphir Feldman; Alan Heath; Ekaterina Svirchevskaya; Gill Cooper; Marina Yermalovich; Philip D Minor
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

2.  Correlation of mutations and recombination with growth kinetics of poliovirus vaccine strains.

Authors:  V Pliaka; Z Kyriakopoulou; D Tsakogiannis; I G A Ruether; C Gartzonika; S Levidiotou-Stefanou; A Krikelis; P Markoulatos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-09-05       Impact factor: 3.267

3.  Long-term excretion of vaccine-derived poliovirus by a healthy child.

Authors:  Javier Martín; Kofi Odoom; Gráinne Tuite; Glynis Dunn; Nicola Hopewell; Gill Cooper; Catherine Fitzharris; Karina Butler; William W Hall; Philip D Minor
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

4.  Evolution of the Sabin type 1 poliovirus in humans: characterization of strains isolated from patients with vaccine-associated paralytic poliomyelitis.

Authors:  M M Georgescu; J Balanant; A Macadam; D Otelea; M Combiescu; A A Combiescu; R Crainic; F Delpeyroux
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

5.  Environmental poliovirus surveillance during oral poliovirus vaccine and inactivated poliovirus vaccine use in Córdoba Province, Argentina.

Authors:  Judith E Mueller; Maël Bessaud; Q Sue Huang; Laura C Martinez; Patricia A Barril; Viviane Morel; Jean Balanant; Judy Bocacao; Joanne Hewitt; Brad D Gessner; Francis Delpeyroux; Silvia V Nates
Journal:  Appl Environ Microbiol       Date:  2009-01-05       Impact factor: 4.792

6.  Impact of exogenous sequences on the characteristics of an epidemic type 2 recombinant vaccine-derived poliovirus.

Authors:  Franck B Riquet; Claire Blanchard; Sophie Jegouic; Jean Balanant; Sophie Guillot; Marie-Anne Vibet; Mala Rakoto-Andrianarivelo; Francis Delpeyroux
Journal:  J Virol       Date:  2008-06-25       Impact factor: 5.103

Review 7.  Molecular typing of enteroviruses: current status and future requirements. The European Union Concerted Action on Virus Meningitis and Encephalitis.

Authors:  P Muir; U Kämmerer; K Korn; M N Mulders; T Pöyry; B Weissbrich; R Kandolf; G M Cleator; A M van Loon
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

8.  Enhanced neurovirulence of borna disease virus variants associated with nucleotide changes in the glycoprotein and L polymerase genes.

Authors:  Yoshii Nishino; Darwyn Kobasa; Steven A Rubin; Mikhail V Pletnikov; Kathryn M Carbone
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

9.  High diversity of poliovirus strains isolated from the central nervous system from patients with vaccine-associated paralytic poliomyelitis.

Authors:  M M Georgescu; F Delpeyroux; M Tardy-Panit; J Balanant; M Combiescu; A A Combiescu; S Guillot; R Crainic
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

10.  Genetic inactivation of poliovirus infectivity by increasing the frequencies of CpG and UpA dinucleotides within and across synonymous capsid region codons.

Authors:  Cara C Burns; Ray Campagnoli; Jing Shaw; Annelet Vincent; Jaume Jorba; Olen Kew
Journal:  J Virol       Date:  2009-07-15       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.